InsidersTradesSigma
Total declarations
Companies
▲ Purchases (7 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by Castagna Michael, Chairman & CEO. Director active across 2 companies, notably Mannkind CORP. Cumulatively, 13 filings have been recorded. Total volume traded: €116k. The latest transaction was filed on 18 May 2022 — Retenue fiscale. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations13 total
€50,05816,434 shares@ €3.0460.0052% mcap17.3% of flow
Common Stock, $.01 Par Value
SEC:0001209191-22-031205:0·
0254,000 shares0
Restricted Stock Unit
SEC:0001209191-22-028680:0·
€67,07727,675 shares@ €2.42370.0070% mcap23.2% of flow
Common Stock,$.01 par value
SEC:0001209191-22-014094:0·
Ideal exit: 25 Nov 2022 (T+270)
€5,1281,804 shares@ €2.84240.0005% mcap3.0% of flow
Common Stock, $0.01 Par Value
SEC:0001209191-22-008267·
Ideal exit: 28 Oct 2022 (T+270)
€5,1281,804 shares@ €2.84240.0005% mcap1.8% of flow
Common Stock, $0.01 Par Value
SEC:0001209191-22-008267:0·
Ideal exit: 28 Oct 2022 (T+270)
€6,6342,334 shares@ €2.84240.0007% mcap3.9% of flow
Common Stock, $0.01 Par Value
SEC:0001209191-22-006414·
Ideal exit: 28 Oct 2022 (T+270)
€6,6342,334 shares@ €2.84240.0007% mcap2.3% of flow
Common Stock, $0.01 Par Value
SEC:0001209191-22-006414:0·
Ideal exit: 28 Oct 2022 (T+270)
€147,67135,358 shares@ €4.17640.015% mcap85.9% of flow
Common Stock, $.01 Par Value
SEC:0001209191-21-053768·
€147,67135,358 shares@ €4.17640.015% mcap51.1% of flow
Common Stock, $.01 Par Value
SEC:0001209191-21-053768:0·
€12,5705,000 shares@ €2.51410.0013% mcap7.3% of flow
Common Stock, $0.01 Par Value
SEC:0001209191-21-049136·
Ideal exit: 26 Apr 2022 (T+270)
€12,5705,000 shares@ €2.51410.0013% mcap4.3% of flow
Common Stock, $0.01 Par Value
SEC:0001209191-21-049136:0·
Ideal exit: 26 Apr 2022 (T+270)
0190,092 shares0
Restricted Stock Unit
SEC:0001209191-21-034452·
0190,092 shares0
Restricted Stock Unit
SEC:0001209191-21-034452:0·
13 of 13 declarations
About Castagna Michael
Castagna Michael is the Chief Executive Officer at MANNKIND CORP. He leads the company and is responsible for overall strategy and operations. His experience in the biopharmaceutical sector is crucial for the development and success of the organization.
